About-cancer / lapaʻau / clinical-hoʻokolohua / maʻi / pahee -ʻaʻaʻa-sarcoma / lapaʻau
Hoʻomaʻamaʻa i nā hoʻokolohua hoʻokalakupua no ka Sarcoma Tissue Kaha
ʻO nā hoʻokolohua hoʻokolohua kahi noiʻi noiʻi e pili ana i ka poʻe. ʻO nā hoʻokolohua hoʻokolohua ma kēia papa inoa no ka hoʻomaʻemaʻe sarcoma aʻa. Kākoʻo ʻia nā hoʻokolohua āpau ma ka papa inoa e NCI.
ʻO ka ʻike pili o NCI e pili ana i nā hoʻokolohua hoʻokolohua e wehewehe i nā ʻano a me nā pae o nā hoʻokolohua a pehea e lawe ai. Nānā nā hoʻāʻo hoʻokolohua i nā ala hou e pale ai, ʻike ai, a mālama ai paha i ka maʻi. E makemake paha ʻoe e noʻonoʻo e pili ana i ka lawe ʻana i ka hoʻokolokolo hoʻokolohua. E kamaʻilio me kāu kauka no ke kōkua i ka hoʻoholo ʻana inā kūpono kekahi iā ʻoe.
ʻO Erdafitinib i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Advanced Tumors Solid, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me FGFR Mutations (A Pediatric MATCH Treatment Trial)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka erdafitinib hana i ka mālama ʻana i nā mea maʻi me nā tumors paʻa, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic i pāhola ʻia i nā wahi ʻē aʻe o ke kino a hoʻi mai a pane ʻole i ka mālama ʻana me nā hoʻololi FGFR. Hiki paha iā Erdafitinib ke hoʻōki i ka ulu ʻana o nā hunaola maʻi ʻaʻai ma ka pale ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 107 mau wahi
ʻO Tazemetostat i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Advanced Tumors Solid, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me EZH2, SMARCB1, a i ʻole SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka hana ʻana o tazemetostat i ka mālama ʻana i nā mea maʻi me nā tumors paʻa, non-hodgkin lymphoma, a i ʻole nā maʻi histiocytic i pāhola ʻia i nā wahi ʻē aʻe o ke kino a hoʻi mai a pane ʻole paha i ka lāʻau lapaʻau a loaʻa iā EZH2, SMARCB1 , a i ʻole SMARCA4 gen mutations. Hiki paha iā Tazemetostat ke hoʻōki i ka ulu ʻana o nā hunaola tumo ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 109 mau wahi
PI3K / mTOR Inhibitor LY3023414 i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Advanced Tumors Solid, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me TSC a i ʻole PI3K / MTOR Hoʻololi (A Pediatric MATCH Lapaʻau Hoʻāʻo)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka hana PI3K / mTOR mea kāohi LY3023414 i ka mālama ʻana i nā mea maʻi me nā tumors paʻa, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic me TSC a i ʻole PI3K / MTOR mutations i pāhola ʻia i nā wahi ʻē aʻe o ke kino (metastatic) a ua hoʻi mai (recurrent) a mai pane ʻole i ka mālama ʻana (refreative). Hiki iā PI3K / mTOR mea kāohi LY3023414 ke hoʻopau i ka ulu ʻana o nā hunaola maʻi maʻi ma ka pale ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 107 mau wahi
Palbociclib i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Rb Positive Advanced Tumors Kūpono, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me ka hoʻoulu ʻana i nā hoʻololi i nā Genes Cycle Cycle (kahi Pediatric MATCH Lapaʻau Hoʻāʻo)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka palbociclib e hana nei i ka mālama ʻana i nā mea maʻi me nā tumo paʻa maikaʻi Rb, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic me ka hoʻololi ʻana i nā hoʻololi (mutations) i nā genes cycle cell i pālahalaha ʻia i nā wahi ʻē aʻe o ke kino a ua hiki hoʻi a pane ʻole i ka lāʻau. Palbociclib hiki ke hoʻopau i ka ulu ʻana o nā hunaola maʻi ʻaʻai e ka pale ʻana i kekahi o nā ʻenemema e pono ai no ka ulu ʻana o ka cell.
Kahi: 97 mau wahi
Larotrectinib i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Advanced Tumors Solid, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me NTRK Fusions (A Pediatric MATCH Treatment Trial)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka hana a larotrectinib i ka mālama ʻana i nā mea maʻi me nā tumors paʻa, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic me nā fusions NTRK i pāhola ʻia i nā wahi ʻē aʻe o ke kino a hoʻi mai a pane ʻole i ka lāʻau. Lohi paha ʻo Larotrectinib i ka ulu ʻana o nā hunaola maʻi ʻaʻai e ka pale ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 109 mau wahi
ʻO Cabozantinib-S-Malate i ka mālama ʻana i nā mea ʻōpio me ka Recomment, Refractory, a i ʻole nā Sarcomas hou, Wilms Tumor, a me nā Tumors Rare ʻē aʻe.
Ke aʻo nei kēia mahele II i ka hana maikaʻi ʻana o cabozantinib-s-malate i ka mālama ʻana i nā mea ʻōpio me nā sarcomas, Wilms tumor, a i ʻole nā tumors ʻē aʻe i hoʻi mai, mai pane i ka lāʻau, a ʻike hou ʻia paha. Hiki paha iā Cabozantinib-s-malate ke hoʻōki i ka ulu ʻana o nā hunaola puʻupuʻu ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ulu ʻana a me ka ulu ʻana o ka moku koko.
Kahi: 137 mau wahi
ʻO Olaparib i ka mālama ʻana i nā mea maʻi me nā Tumors Pae holomua a i ʻole Refractory Advanced Tumors, Non-Hodgkin Lymphoma, a i ʻole nā maʻi maʻi Histiocytic me nā kīnā i ka DNA Damage hoʻomaikaʻi Genes.
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka olaparib hana i ka mālama ʻana i nā mea maʻi me nā tumors paʻa, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic me nā kīnā o ka deoxyribonucleic acid (DNA) hōʻino i nā genes hoʻoponopono i pālahalaha ʻia i nā wahi ʻē aʻe o ke kino (holomua) a ua hoʻi mai (relapsed) a mai pane ʻole i ka lapaʻau (refreative). Hiki iā Olaparib ke ho'ōki i ka ulu ʻana o nā hunaola tumele ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 105 mau wahi
ʻO Vemurafenib i ka mālama ʻana i nā mea maʻi me ka hoʻi hou ʻana a i ʻole Refractory Advanced Tumors Solid, Non-Hodgkin Lymphoma, a i ʻole nā Histiocytic Disorder me BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Ke nānā nei kēia pae II Pediatric MATCH hoʻokolohua i ka maikaʻi o ka vemurafenib e hana ai i nā mea maʻi me nā tumors paʻa, non-Hodgkin lymphoma, a i ʻole nā maʻi histiocytic me nā BRAF V600 mutations i pāhola ʻia i nā wahi ʻē aʻe o ke kino a hoʻi mai a pane ʻole i ka lāʻau. Hiki paha iā Vemurafenib ke hoʻōki i ka ulu ʻana o nā hunaola tumo ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 106 mau wahi
Atezolizumab i ka mālama ʻana i nā mea maʻi me ka mea hou i hōʻike ʻia a me Metastatic Alveolar Palupalu ʻĀpana Sarcoma i hiki ʻole ke hemo ʻia e ke ʻoki kino.
Ke aʻo nei kēia mahele II i ka maikaʻi o ka hana a atezolizumab i ka mālama ʻana i nā mea maʻi me ka sarcoma ʻāpana palupalu i mālama ʻole ʻia, a ua hoʻolaha ʻia mai kahi i hoʻomaka ai i nā wahi ʻē aʻe o ke kino a ʻaʻole hiki ke hemo e ke ʻoki. Immunotherapy me nā monoclonal antibodies, e like me atezolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumola aola e ulu a pālahalaha aʻe
Kahi: 39 mau wahi
ʻO Nivolumab a me Ipilimumab i ka mālama ʻana i nā mea maʻi me ka HIV Associated Relapsed a i ʻole Refractory Classical Hodgkin Lymphoma a i ʻole Tumors paʻa paʻa i Metastatic a i ʻole hiki ke hemo ʻia e ka ʻoki kino.
Ke nānā nei kēia mahele hoʻokolohua i nā hopena a me ka hopena maikaʻi loa o ka nivolumab ke hāʻawi ʻia me ipilimumab i ka mālama ʻana i nā mea maʻi me ka maʻi pale maʻi (HIV) e pili ana i ka lymphoma Hodgkin kahiko i hoʻi mai ma hope o kahi manawa o ka hoʻomaikaʻi a pane ʻole paha i ka lapaʻau. ua pālahalaha aku i nā wahi ʻē aʻe o ke kino a i ʻole hiki ʻole ke wehe ʻia e ke ʻoki. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ipilimumab a me nivolumab, ke kōkua i ke kino o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūhaka tumo. ʻO Ipilimumab kahi maʻi ʻino e kūʻē i kahi mole i kapa ʻia ʻo cytotoxic T-lymphocyte antigen 4 (CTLA-4). Mālama ʻo CTLA-4 i kahi ʻāpana o kāu ʻōnaehana pale pale ma ka hoʻopau ʻana iā ia. ʻO Nivolumab kahi ʻano antibody i kikoʻī no ka make pūnaewele hoʻonaninani kanaka 1 (PD-1), he protein i kuleana no ka luku ʻia ʻana o nā hunaola pale. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka ipilimumab me ka nivolumab i ka mālama ʻana i nā mea maʻi me ka maʻi HIV e pili ana i ka lymphoma Hodgkin a i ʻole nā tumors paʻa e hoʻohālikelike ʻia me ka ipilimumab me ka nivolumab wale nō.
Kahi: 28 mau wahi
MDM2 Inhibitor AMG-232 a me Radiation Therapy i ka mālama ʻana i nā mea maʻi me ka Tissue Sarcoma Soft Tissue
Ke aʻo nei kēia mahele ʻo Ib i nā hopena o ka MDM2 mea kāohi AMG-232 a me ka radiation therapy i ka mālama ʻana i nā mea maʻi me ka sarcoma puʻupuʻu palupalu. Hiki i ka MDM2 mea hoʻopaʻa AMG-232 ke hoʻopau i ka ulu ʻana o nā hunaola maʻi ʻaʻai e ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. Ke hāʻawi nei i ka mea kāohi MDM2 iā AMG-232 a me ka radiation therapy ma mua o ke kahakaha ʻana e hana i ka liʻiliʻi o ka tumo a hoʻoliʻiliʻi i ka nui o nā mea maʻamau e pono e hemo.
Kahi: 27 mau wahi
ʻO Nivolumab me ka ʻole o Ipilimumab i ka mālama ʻana i nā mea ʻōpio me nā Tumors Solid a Refractory Solid paha a i ʻole Sarcomas
Ke aʻo nei kēia mahele I / II i nā hopena a me ka hopena maikaʻi loa o ka nivolumab ke hāʻawi ʻia me a i ʻole ʻole ipilimumab e ʻike i ke ʻano o kā lākou hana ʻana i ka mālama ʻana i nā mea ʻōpio me nā tumors paʻa a i ʻole nā sarcomas i hoʻi mai (recurrent) a i ʻole e pane i ka mālama refractory). Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab a me ka ipilimumab, ke kōkua i ka ʻōnaehana pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora. ʻAʻole i ʻike ʻia inā ʻoivolumab ka hana ʻoi aku ka maikaʻi a i ʻole me ka ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors paʻa hou a refactory a i ʻole sarcomas.
Kahi: 24 mau wahi
Selinexor i Advanced Liposarcoma
ʻO kēia kahi randomized, multicenter, blind-blind, placebo-control, Phase 2-3 hoʻopaʻa haʻawina o nā mea maʻi i ʻike ʻia me ka liposarcoma hiki ʻole ke hoʻopau ʻia kiʻekiʻe. Ma kahi o 279 ka nui o nā mea maʻi e hoʻokolohua ʻia e hoʻopaʻa i ka mālama ʻana (selinexor a i ʻole placebo).
Kahi: 21 mau wahi
(VOYAGER) Ke aʻo ʻana iā Avapritinib vs Regorafenib i nā mea maʻi me ka unresectable a metastatic GIST kiʻekiʻe loa.
ʻO kēia kahi lepili hāmama, ʻike ʻole ʻia, Phase 3 hoʻopaʻa haʻawina i nā mea maʻi me GIST (holomua GIST) holomua kūloko o avapritinib (ʻo BLU-285 ka inoa) a me regorafenib i nā maʻi i mālama mua ʻia me imatinib a me 1 a i ʻole 2 mau TKI ʻē aʻe.
Kahi: 14 mau wahi
ʻO kahi papahana 1 o ka EZH2 Inhibitor Tazemetostat i nā kumuhana Pediatric me ka hoʻi hou ʻana a i ʻole Refractory INI1-Nā Tumors Negative a i ʻole Synovial Sarcoma
ʻO kēia kahi Māhele I, ka lepili hāmama, ka hoʻonui ʻana o ka lāʻau a me ka hoʻonui ʻana o ka lāʻau me kahi lāʻau oral BID o tazemetostat. E nānā ʻia nā kumuhana no ke kūpono i loko o 14 mau lā o ka hoʻolālā mua o ka tazemetostat. ʻO kahi pōʻaiapuni e 28 lā. E loiloi ʻia ka loiloi pane ma hope o 8 mau pule o ka hoʻomaʻamaʻa a ma hope ma kēlā me kēia 8 mau pule ʻoiai e hoʻopaʻa haʻawina ana. He ʻelua ʻāpana o ke aʻo ʻana: Ka Hoʻonui ʻana o Dose a me ka Hoʻonui Dose. ʻO ka piʻi ʻana o ka hana no nā kumuhana me nā maʻi ʻino hou i hoʻi hou ʻia: - Rhorsid tumors (ATRT) :
Kahi: 14 mau wahi
ʻO Adavosertib a me Irinotecan Hydrochloride i ka mālama ʻana i nā mea ʻōpio me nā Tumors paʻa a Refractory paha.
Ke aʻo nei kēia mahele I / II i nā hopena a me ka mahele lāʻau maikaʻi loa o ka adavosertib a me ka irinotecan hydrochloride i ka mālama ʻana i nā mea ʻōpio me nā tumors paʻa i hoʻi mai (relapsed) a i ʻole pane i ka haʻaheo maʻamau (refractory). Hiki i ka Adavosertib a me ka irinotecan hydrochloride ke hoʻōki i ka ulu ʻana o nā hunaola puʻupuʻu ma ke kāpae ʻana i kekahi o nā enzyme e pono ai no ka ulu ʻana o ka cell.
Kahi: 22 mau wahi
ʻO kahi Phase III Trial o Anlotinib ma Metastatic a i ʻole Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma a me Synovial Sarcoma
Loiloi kēia noiʻi i ka palekana a me ka pono o AL3818 (anlotinib) hydrochloride i ka mālama ʻana i ka sarcoma ʻāpana alveolar a i ʻole holomua holomua (ASPS), leiomyosarcoma (LMS), a me ka sarcoma synovial (SS). E loaʻa i nā mea komo āpau me ASPS ka hōʻailona hāmama iā AL3818. I nā mea komo me LMS a i ʻole SS, AL3818 e hoʻohālikelike ʻia me IV dacarbazine. ʻElua hapakolu o nā mea e komo ana e loaʻa iā AL3818, kahi hapakolu o nā mea e komo ana e loaʻa iā IV dacarbazine.
Kahi: 14 mau wahi
ʻO Nab-Paclitaxel a me Gemcitabine Hydrochloride i ka mālama ʻana i nā ʻōpio a i ʻole nā ʻōpio me ka Osteosarcoma hou a Refractory paha, ʻo Ewing Sarcoma, ʻo Rhabdomyosarcoma, a ʻo Soft Tissue Sarcoma paha.
Ke aʻo nei kēia mahele II i ka maikaʻi o ka hana nab-paclitaxel a me gemcitabine hydrochloride i ka mālama ʻana i nā ʻōpio a i ʻole ʻōpio me ka osteosarcoma, ʻo Ewing sarcoma, rhabdomyosarcoma, a i ʻole sarcoma mea palupalu i hoʻi mai a pane ʻole paha i ka lāʻau. ʻO nā lāʻau i hoʻohana ʻia i ka chemotherapy, e like me nab-paclitaxel a me gemcitabine hydrochloride, hana i nā ala like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, ma ka make ʻana paha i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kāpae ʻana iā lākou mai ka hoʻolaha ʻana.
Kahi: 18 mau wahi
ʻO Olaparib a me Temozolomide i ka mālama ʻana i nā maʻi me ka holomua, Metastatic, a i ʻole Unresectable Uterine Leiomyosarcoma
Ke aʻo nei kēia mahele II i ka olaparib a me temozolomide i ka mālama ʻana i nā mea maʻi me ka leiomyosarcoma uterine (LMS) i pālahalaha ʻia i nā wahi ʻē aʻe o ke kino (holomua a metastatic paha) a i ʻole hiki ke lawe ʻia e ka ʻoki kino (unreserctable). Hiki iā Olaparib ke ho'ōki i ka ulu ʻana o nā hunaola tumele ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. Hana ʻia nā lāʻau i loko o ka chemotherapy, e like me temozolomide, i nā ʻano hana like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, a i ʻole ma ka luku ʻana i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kū ʻana iā lākou mai ka hoʻolaha ʻana ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka olaparib a me temozolomide ma mua o ka hāʻawi ʻana i nā lāʻau ʻelua i ka mālama ʻana i nā mea maʻi me LMS.
Kahi: 12 mau wahi
ʻO kahi palekana, Tolerability a me PK Study o DCC-2618 i nā mea maʻi me nā maʻi maʻi holomua
ʻO kēia kahi Phase 1, open-label, first-in-human (FIH) dose-escalation study i hoʻolālā ʻia e loiloi i ka palekana, hoʻomanawanui, pharmacokinetics (PK), pharmacodynamics (PD) a me ka hana antitumor mua o DCC-2618, lawelawe waha ʻia. (PO), i nā mea maʻi makua me nā maʻi kūpilikiʻi loa. Aia i loko o ka noiʻi nā ʻāpana 2, kahi pae hoʻonui ʻana a me kahi manawa hoʻonui.
Kahi: 12 mau wahi
ʻO Nelfinavir Mesylate i ka mālama ʻana i nā mea maʻi me Kaposi Sarcoma
Ke aʻo nei kēia pae hoʻokolohua pae II i ke ʻano o ka maikaʻi o ka nelfinavir mesylate e hana ai i ka mālama ʻana i nā mea maʻi me ka sarkoma Kaposi. Hiki iā Nelfinavir mesylate ke hoʻōki i ka ulu ʻana o nā hunaola tumo ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell.
Kahi: 11 mau wahi
sEphB4-HSA i ka mālama ʻana i nā maʻi me Kaposi Sarcoma
Ke aʻo nei kēia mahele II i ka recombinant ʻo EPB4-HSA fusion protein (sEphB4-HSA) i ka mālama ʻana i nā mea maʻi me ka sarkoma Kaposi. Hiki i ka recombinant EphB4-HSA fusion protein ke ālai i ka ulu ʻana o nā kīʻaha koko e hāʻawi i ke koko i ka maʻi ʻaʻai, a pale paha i nā hunaola maʻi maʻi mai ka ulu ʻana.
Kahi: 10 mau wahi
ʻO kahi pae II, kahi aʻo Multicenter o ka EZH2 Inhibitor Tazemetostat i nā kumuhana makua me INI1-Negative Tumors a i ʻole Relapsed / Refractory Synovial Sarcoma
ʻO kēia kahi Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID i lawelawe waha ʻia i nā pōʻai mau lā 28 mau lā. E mālama ʻia ana ka nānā ʻana i nā kumuhana e hoʻoholo i ka pono no ke aʻo ʻana ma loko o 21 mau lā o ka lāʻau i hoʻolālā mua ʻia o ka tazemetostat. E kākau inoa ʻia nā kumuhana kūpono i loko o kekahi o nā ʻelima huakaʻi e pili ana i ke ʻano tumo: ʻike ʻia ʻo ka tumo rhaboid malignant o ka ovary [MRTO] - Cohort 2 (Pani ʻia no ke kākau inoa ʻana): Hoʻopaʻi hou ʻia a hoʻomaha hou ʻia kahi sarcoma synovial me SS18-SSX hoʻoponopono - Cohort 3 (Pani ʻia no ke kākau inoa ʻana) loaʻa o ka hana (GOF) hoʻololi, me:
Kahi: 12 mau wahi
SARC024: Kahi Blanket Protocol e hoʻopaʻa ai i nā Regorafenib waha i nā mea maʻi me nā subcoma Sarcoma i wae ʻia.
ʻOiai ua ʻae ʻia ka regorafenib no ka hoʻohana ʻana i nā mea maʻi i loaʻa ka GIST holomua ʻoiai imatinib a me / a i ʻole sunitinib ma ke kumu o ka ʻikepili II a me ka pae III, ʻaʻole i nānā ʻia i kahi ʻano ʻōnaehana i nā mea maʻi me nā ʻano sarcoma ʻē aʻe. Hāʻawi ʻia i ka hana o ka sorafenib, sunitinib a me ka pazopanib i nā sarcomas a nā mea palupalu, a me nā hōʻike o ka hana o sorafenib i ka sarcoma osteogenic a ʻo sarcoma paha ʻo Ewing / Ewing, aia kekahi mea e nānā ai iā SMOKI ʻē aʻe ma mua o GIST. Hoʻomaopopo pū ʻia ʻo SMOKI (nā mole mole kinole oral liʻiliʻi liʻiliʻi) e like me regorafenib, sorafenib, pazopanib, a me sunitinib i loaʻa nā panela o nā kinase i kāpae ʻia i ka manawa like. ʻOiai ʻaʻole like,
Kahi: 10 mau wahi
Palekana, Tolerability a me nā Pharmacokinetics o kahi Anti-PD-1 Monoclonal Antibody i nā kumuhana me nā maʻi ʻōpio kiʻekiʻe.
ʻO ka pahuhopu nui e nānā i ka palekana a me ka hoʻomanawanui ʻana o Toripalimab i nā kumuhana me nā ʻano maʻi kūpilikiʻi like ʻole a e loiloi i ka lāʻau Phase 2 i ʻōlelo ʻia. ʻO nā pahuhopu kiʻekiʻe ke: 1) wehewehe i ka moʻoʻōlelo o ka pharmacokinetic (PK) o Toripalimab, 2) loiloi i ka hana antitumor o Toripalimab; 3) e hoʻoholo i ka palekana o Toripalimab; 4) loiloi i ke ola holoʻokoʻa. ʻO nā pahuhopu mākaʻikaʻi e: 1) loiloi i nā biomarkers i hiki ke hoʻopili me ka hana o Toripalimab, 2) loiloi i nā hopena pharmodnamic o Toripalimab i ka mea i loaʻa iā ia, ka make ʻana o ka pūnaewele 1 (PD-1), a me nā hopena o ka ʻōnaehana pale. 3) loiloi i ka pono o PD-L1 & nā māka mākaʻikaʻi hou aʻe ma ke ʻano he biomarkers i hiki ke kōkua i ke koho ʻana i nā kumuhana kūpono no ka TAB001 therapy,
Kahi: 9 mau wahi
